PolyPeptide well positioned with multi-site manufacturing and development network and rich pipeline
Rapid portfolio shift driven by GLP-1
Growth across therapeutical areas, with mix shifting towards metabolic and large pharma customers
Partnering for growth
Three new large agreements concluded in 2023; together with agreement previously announced in December 2022, they have the potential to double PolyPeptide’s revenue
2023 – transformation underway with record revenue growth of 43% in H2 2023 vs H1 2023.